Arthritis & Rheumatism · 1999 · 78 citations · 47 references
Life SciencesImmunologyInternal MedicineAutoimmunityMonoclonal AntibodiesRheumatologyAutoimmune InflammationAutoimmune Rheumatic DiseasesImmune-mediated Inflammatory DiseasesMonoclonal Antibody TherapyRheumatoid ArthritisTherapeutic Monoclonal AntibodiesCd4 Positive T CellsCd8 Positive T CellsInterferon Gamma ProductionInterferon-gamma ResponsesProinflammatory Cytokine ModulationRheumatoid Arthritis TherapyTh1 Th2 BalanceTumor Necrosis Factor Therapy
OBJECTIVE: In rheumatoid arthritis (RA), treatment with tumor necrosis factor alpha (TNFalpha) binding agents has proven to be highly effective. Downregulation of the proinflammatory cytokine cascade and a reduced migration of leukocytes into the joints have been proposed as modes of action of TNFalpha blockade. We investigated whether alterations in the number of circulating pro- and antiinflammatory T cell subsets contribute to the therapeutic effect of monoclonal antibodies (mAb) against TNFalpha in RA patients. METHODS: Phenotypic analysis of peripheral blood T cell subsets was performed on blood from RA patients before and after treatment with an anti-TNFalpha mAb. RESULTS: An accumulation of primed CD45RA- T cells of both the CD4+ and the CD8+ T cell population was seen shortly after treatment. Most notably, within the CD4+,CD45RA- T cell subset, the number of interferon-gamma-producing T cells was significantly increased after anti-TNFalpha mAb treatment, resulting in a significant rise in the Th1:Th2 ratio. In addition, an increase in the number of CD4+ T cells expressing the homing receptor CD49d in high density was observed after treatment, which correlated positively with the increase in the Th1:Th2 ratio. Conclusion. We show that the Th1:Th2 ratio in the peripheral blood is raised by anti-TNFalpha mAb treatment.
47
Revised Criteria for the Classification of Rheumatoid Arthritis
Frank C. Arnett · Orthopaedic Nursing · 1990 · 7.7K citations
Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells
Dörte Hamann, Paul A. Baars, M.H.G. Rep et al. · The Journal of Experimental Medicine · 1997 · 1.4K citations · Full text